Highest-materiality recent filing
AnaptysBio Q1 net loss $52.9M; completes First Tracks spin-off, Jemperli royalties up 44%
Net loss per share $1.84 vs $1.28 YoY; collaboration revenue $25.6M (Jemperli royalties $24.7M, +44%).
AnaptysBio pro forma continuing ops net income $114.9M after First Tracks spin-off
Pro forma continuing ops net income $114.9M for FY2025; basic EPS $3.99, diluted $3.07.
Each ANAB shareholder received one TRAX share for each share held on record date April 6, 2026.
AnaptysBio approves spin-off of First Tracks Biotherapeutics; distribution set for April 20, 2026
Anaptys stockholders to receive one share of First Tracks Bio (TRAX) per ANAB share held on April 6, 2026; distribution expected pre-market April 20, 2026.
AnaptysBio plans spin-off of biopharma as First Tracks (TRAX); Q4 net income $49.6M
Spin-off of biopharma portfolio into First Tracks Biotherapeutics (TRAX) on track for Q2 2026, potentially late April.
AnaptysBio reports preliminary cash & investments of ~$310M as of Dec 31, 2025
Preliminary unaudited cash, equivalents and investments ~$310M as of Dec 31, 2025.
AnaptysBio sues Tesaro and GSK for breach of collaboration agreement on dostarlimab
AnaptysBio filed suit in Delaware Chancery Court on Nov 20, 2025, alleging material breach of the Collaboration Agreement by Tesaro and GSK.
AnaptysBio sues Tesaro and GSK for breach of Jemperli collaboration; countersuit filed
AnaptysBio alleges Tesaro breached exclusivity by conducting trials with competing PD-1 antagonists (e.g., Keytruda) and failing to maximize Jemperli return.
Board authorizes $100M increase in stock repurchase plan; $106.4M total capacity
Board amended Stock Repurchase Plan to allow up to $100M additional repurchases, plus $6.4M remaining under prior $75M plan.
AnaptysBio's rosnilimab fails Phase 2 UC trial; trial discontinued
Rosnilimab did not meet primary (mMS change) or key secondary endpoints at Week 12 in moderate-to-severe UC.
AnaptysBio plans to separate biopharma ops from royalty assets by YE 2026; Q3 net income $15.1M
Intent to split into two public companies, one holding Jemperli royalties and milestones, the other advancing pipeline assets.
AnaptysBio to split into two public companies by end of 2026; royalty assets separate from biopharma
CEO Daniel Faga expected to lead Biopharma Co; Royalty Co holds Jemperli (GSK) and imsidolimab (Vanda) royalties.
AnaptysBio Q2 net loss narrows to $38.6M; rosnilimab Phase 2b RA data positive
Net loss $38.6M ($1.34/sh) vs $46.7M ($1.71) YoY; collaboration revenue $22.3M, up from $11.0M.
AnaptysBio rosnilimab Phase 2b RA data shows best-in-disease profile with JAK-like efficacy
424-patient Phase 2b trial: rosnilimab achieved JAK-like efficacy on CDAI LDA, remission, and ACR70 through six months.
Cash and investments $383M as of March 31, 2025, with cash runway through year-end 2027.
AnaptysBio authorizes up to $75M stock repurchase plan
Board authorized $75M buyback of outstanding common stock.
AnaptysBio reports positive rosnilimab RA data; Q4 net loss narrows to $21.8M; cash $420.8M
Rosnilimab achieved statistical significance on primary endpoint (DAS28-CRP) at Week 12 in Phase 2b RA trial; highest-ever CDAI LDA responses reported.
Phase 2b RENOIR trial (n=424) met primary endpoint (mean DAS-28 CRP change at week 12) across all three doses vs placebo (p<0.01).
AnaptysBio licenses imsidolimab to Vanda for $15M upfront; BLA/MAA prep underway
Anaptys receives $10M upfront and $5M for drug supply; eligible for up to $35M in milestones and 10% royalty on net sales.
AnaptysBio Phase 2B trial of ANB032 fails endpoints in atopic dermatitis; cash ~$415M
ANB032 did not meet primary endpoint EASI-75 or any secondary endpoints at Week 14 in 201-patient ARISE-AD trial.
AnaptysBio Q3 net loss $1.14/shr; cash $458M; Phase 2b data catalysts ahead
Net loss $32.9M ($1.14/shr) vs $37.3M ($1.41/shr) year-ago; nine-month loss $4.46/shr.
AnaptysBio prices public offering of 2.75M shares at $36.50 for ~$100M gross
Gross proceeds ~$100M from sale of 2,750,498 shares at $36.50 per share.
AnaptysBio Q2 net loss $46.7M; cash $393.5M; ANB032 Phase 2b enrollment complete, data Dec 2024
Net loss of $46.7M ($1.71 per share) for Q2 2024, vs $39.8M loss ($1.50) in Q2 2023.
Q1 2024 net loss $43.9M ($1.64/share) vs $44.3M ($1.58/share) in Q1 2023; revenue $7.2M from Jemperli royalties.
Upfront cash payment of $7M ($4M license fee + $3M for GMP supply of ANB101).
AnaptysBio Q3 net loss $37.3M ($1.41/sh); imsidolimab Phase 3 GPP hits primary endpoint
Net loss $37.3M ($1.41/sh) vs $33.5M ($1.18/sh) YoY; R&D spend rose to $30.9M.
53.3% of imsidolimab-treated patients achieved GPPPGA 0/1 at Week 4 vs 13.3% placebo (p=0.0131).
AnaptysBio Q2 net loss $39.8M; imsidolimab Phase 3 enrollment complete
Q2 net loss $39.8M ($1.50/sh) vs $32.6M ($1.15) YoY; six-month loss $84.1M ($3.08/sh).
AnaptysBio reports Q1 net loss of $44.3M; initiates Phase 2b for ANB032 in atopic dermatitis
Net loss of $44.3M ($1.58 per share) vs $36.3M loss in Q1 2022; R&D expenses rose to $35.0M.
Net loss for Q4 2022 was $26.4M ($0.93 per share); full year net loss $128.7M ($4.57 per share), compared to $57.8M in 2021.
AnaptysBio authorizes $50M stock repurchase plan; cash >$575M
Board authorized repurchase of up to $50M of common stock through Dec 31, 2023.
AnaptysBio ends alopecia areata trial; launches Phase 2b for RA and atopic dermatitis
Rosnilimab Phase 2a in alopecia areata failed to achieve target efficacy (no patient SALT<20); further development discontinued.
AnaptysBio Q3 net loss $33.5M ($1.18/sh); cash $590.5M; alopecia areata data Q1 2023
Net loss $33.5M (Q3 2022) vs $6.7M (Q3 2021); loss/share $1.18 vs $0.24.
AnaptysBio sells Zejula royalty rights to DRI Healthcare for $35M upfront
Received $35M upfront from DRI for all future Zejula royalties from GSK (effective July 2022).
Imsidolimab HARP Phase 2 fails to beat placebo in hidradenitis suppurativa; HS development halted
Imsidolimab did not improve primary endpoint (AN count change) or HiSCR50 vs placebo at Week 16 in moderate-to-severe HS.
On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026.
On September 15, 2023, the Board appointed John Orwin as a Class II director, a member of the Nominating and Corporate Governance Committee and Chairman of the Board, effective immediately.
On September 14, 2023, James N. Topper, M.D., Ph.D., advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that he would resign as a Class II director and as Chairman of the Board, effective on September 15, 2023.
On April 3, 2023, the Board appointed Rita Jain, M.D. as a Class II director and as a member of the Compensation Committee, effective immediately.
On April 1, 2023, Laura J. Hamill advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that she would resign as a Class II director of the Board, effective on April 1, 2023 (the “ Resignation ”).
the Company appointed Daniel Faga, a Class I director of the Board, to serve as Interim President and Chief Executive Officer of the Company, effective as of March 21, 2022.
On March 20, 2022, Hamza Suria, provided notice to the board of directors (the “Board”) of AnaptysBio, Inc. (the “Company”) of his resignation as President and Chief Executive Officer and as a Class II director of the Company, effective immediately.
On November 26, 2021, AnaptysBio, Inc. (the “Company”) appointed Mr. Daniel Faga, as a Class I director on its board of directors (the “Board”), effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material